Menu Search
Equities

Pharmadrug Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
G11:FRA

Pharmadrug Inc

Actions
  • Price (EUR)0.0005
  • Today's Change-0.001 / -50.00%
  • Shares traded2.83k
  • 1 Year change0.00%
  • Beta0.2285
Data delayed at least 15 minutes, as of Feb 16 2026 07:12 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

PharmaDrug Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on the research, development and commercialization of controlled substances and natural medicines, such as psychedelics and previously approved drugs. The Company’s subsidiary, Sairiyo Therapeutics (Sairiyo), is a biotech company that specializes in researching and reformulating established natural medicines. Sairiyo is engaged in the development of its patented reformulation of cepharanthine, a drug that has shown substantial third-party validated potential for the treatment of infectious diseases and rare cancers. Sairiyo is also conducting research and development (R&D) in the psychedelics space for the treatment of non-neuropsychiatric conditions. It also owns 100% of SecureDose Synthetics Inc. a pharmaceutical research and development company focused on the development of synthetic formulations of existing drugs for potential commercialization and distribution.

  • Revenue in CAD (TTM)0.00
  • Net income in CAD-243.85k
  • Incorporated2011
  • Employees--
  • Location
    Pharmadrug Inc77 King St. West, Suite 2905TORONTO M5K 1H1CanadaCAN
  • Phone+1 (647) 202-1824
  • Fax+1 (416) 765-0029
  • Websitehttps://pharmadrug.ca/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.